Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Johnson & Johnson 3Q Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Johnson & Johnson 3Q Results

Growth in the quarter driven by DARZALEX, CARVYKTI, ERLEADA in Oncology, TREMFYA and SIMPONI in Immunology, and SPRAVATO in Neuroscience.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Johnson & Johnson

Johnson & Johnson

3Q Revenues: $24.0 billion (+7%)

3Q Earnings: $5.2 billion (+91%)

YTD Revenues: $69.6 billion (+5%)

YTD Earnings: $21.7 billion (+104%)

Comments: Growth in the quarter was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. 

DARZALEX sales were up 22% to $3.7 billion. CARVYKTI sales were up 84% to $524 million. ERLEADA sales were up 18% to $936 million. TREMFYA sales were $1.4 billion, up 41%. SIMPONI/SIMPONI ARIA sales were $687 million, up 33%. SPRAVATO sales were $459 million, up 62%

Growth was partially offset by sales declines for STELARA in Immunology, down 41% to $1.6 billion, and IMBRUVICA in Oncology, down 8% to $695 million. INVEGA SUSTENNA sales were down 11% to $929 million.

Earnings exclude intangible amortization expense and special items. Earnings reflect R&D program exits in infectious diseases and vaccines including the discontinuation of its RSV adult vaccine program, hepatitis and HIV development. The restructuring expense of $19 million in 3Q224 and $100 million 3Q24 YTD included the termination of partnered and non-partnered program costs, asset impairments and asset divestments.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics